Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 20, 2020

Israel approves import of generic of AbbVie’s HIV drug for Covid-19

Israel health ministry has approved the licensing of a generic version of AbbVie’s HIV drug Kaletra to treat Covid-19, as the cases in the country exceed 500.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Israel health ministry has approved the licensing of a generic version of AbbVie’s HIV drug Kaletra to treat Covid-19, as the cases in the country exceed 500.

The patent for the anti-viral drug Kaletra expires in Israel in 2024, while the patent in other countries, including India, already expired.

Israel attorney general for the first time allowed the use of a generic version of a patent-protected drug, noted Reuters.

To protect the patent, the generic medication, imported from countries where patent expired, will not be given to HIV patients but only be used for treating the novel coronavirus infection.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

According to a China study published in the New England Journal of Medicine, Kaletra, a combination of lopinavir and ritonavir, failed to demonstrate therapeutic benefits in Covid-19 patients.

However, the Israel Ministry of Health provided a preliminary permit saying that the drug could be a potential coronavirus treatment.

Israel Justice Ministry was quoted as saying: “The company with the patent and the official importer in Israel are not able to supply the necessary inventory for this drug, which is very much in demand all over the world these days.

“Therefore, the state will be able to import generic substitutes from countries where the patent has expired.”

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU